The prognostic effect of LINC00152 for cancer: a meta-analysis
Metrics: PDF 1145 views | HTML 1357 views | ?
Fei-Yu Quan1,*, Jun Jiang2,*, Yi-Fan Zhai3,*, Bing Li2, Xin-Hua Wu4 and Wei Nie4
1The 425th Hospital of PLA, Sanya, Hainan, China
2Department of Respiratory Medicine, Shanghai Changzheng Hospital, Second Military Medical University, Shanghai, China
3Department of Respiratory Medicine, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China
4Department of Internal Medicine, The 425th Hospital of PLA, Hainan, China
*These authors contributed equally to this work
Bing Li, email: [email protected]
Xin-Hua Wu, email: [email protected]
Wei Nie, email: [email protected]
Keywords: cancer, LINC00152, biomarker, OS
Received: July 12, 2017 Accepted: July 30, 2017 Published: August 10, 2017
No meta-analysis has been performed to evaluate the association between LINC00152 and the survival of patients with cancers. We thus carried out this study. The online databases, such as PubMed, EMBASE, and the Cochrane controlled trials register, were searched to identify relevant articles. Dichotomous data were analyzed using the odds ratio (OR) as the summary statistic. The association between LINC00152 and survival of cancer was analyzed by pooling the hazard ratio (HR) with its corresponding 95% confidence interval (CI). Nine studies with 862 patients with cancer were included in this meta-analysis. The expression of LINC00152 was not associated with the age of patients (OR = 0.79, 95% CI = 0.55–1.14) and gender (OR = 1.08, 95% CI = 0.74–1.58). However, we found significant positive associations between LINC00152 and lymph node metastasis (OR = 2.54, 95% CI = 1.54–4.18) and TNM stage (OR = 2.32, 95% CI = 1.36–3.93). Furthermore, the expression of LINC00152 was significantly associated with tumor recurrence (OR = 3.32, 95% CI = 1.98–5.57) and shorter OS (HR = 1.94, 95% CI = 1.25–3.02). In conclusion, the results of this meta-analysis suggest that LINC00152 might be a biomarker for shorter OS and tumor recurrence in cancers.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.